Investors focused on the Medical space have likely heard of Athenex , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Athenex is a member of our Medical group, which includes 761 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ATNX is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for ATNX's full-year earnings has moved 3.56% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

Based on the latest available data, ATNX has gained about 21.45% so far this year. In comparison, Medical companies have returned an average of 2.97%. This means that Athenex is outperforming the sector as a whole this year.

Breaking things down more, ATNX is a member of the Medical - Biomedical and Genetics industry, which includes 281 individual companies and currently sits at #104 in the Zacks Industry Rank. On average, this group has gained an average of 0.72% so far this year, meaning that ATNX is performing better in terms of year-to-date returns.

Investors with an interest in Medical stocks should continue to track ATNX. The stock will be looking to continue its solid performance.